Skip to content

Evaluation of the effect of regular patient guidance by insurance pharmacy pharmacists and provision of information to hospitals on heart failure management

Evaluation of the effect of regular patient guidance by insurance pharmacy pharmacists and provision of information to hospitals on heart failure management - Evaluation of the Effectiveness of Insurance Pharmacy Pharmacist Intervention for Heart Failure Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000046750
Enrollment
200
Registered
2022-02-01
Start date
2022-02-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic heart failure

Interventions

Guidance, medical treatment support, and information provision by an insurance pharmacy pharmacist once every two weeks for one year Interventions as existing for one year

Sponsors

Tosei general hospital
Lead Sponsor
Nagoya City University Graduate School of Pharmaceutical Sciences
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients who were hospitalized for heart failure treatment at the time of consent acquisition and are scheduled to visit the Department of Cardiology as an outpatient for heart failure after discharge. 2.Patients who have been diagnosed as AHA stage C heart failure. 3. Patients who are 18 years old or older at the time of obtaining consent. 4. Patients who have a specific pharmacy to dispense prescriptions.

Exclusion criteria

Exclusion criteria: 1.Patients who have difficulty in voluntarily agreeing to participate in this study. 2. Patients with serious disorders (renal, hepatic, hematological, respiratory, digestive, neuropsychiatric, metabolic, etc.) who are judged by the attending physician to be ineligible for this study. 3. Patients who have difficulty or refuse to come to our hospital. 4. Other patients who are judged by the attending physician to be ineligible for this study.

Design outcomes

Primary

MeasureTime frame
Initial readmissions, emergency room visits and fatal events due to worsening of chronic heart failure

Countries

Japan

Contacts

Public ContactJunichi Terashima

Tosei general hospital Pharmaceutical department

c212806@ed.nagoya-cu.ac.jp+81-561-82-5101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026